What Ozempic actually costs, in plain language

What this guide covers

The list price, what people actually pay with insurance, the manufacturer's own self-pay channel, and why the same pen has five different prices. A calm map of the money side, with no affiliate stake in any of it. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The honest disclaimer first. Drug prices in the United States move constantly, programs open and close, and what you pay depends on your insurance, your diagnosis, and the channel you buy through. Everything below is accurate as of June 2026 and framed in ranges for exactly that reason. Treat this page as a map of the system, then verify the current number for your situation with your pharmacy, your plan, and the manufacturer's own pricing pages. Peptips takes no money from drug makers, pharmacies, or telehealth sellers, so nothing here is steering you toward a buying path.
• The list price, and why almost nobody pays it. Ozempic's U.S. list price has sat near one thousand dollars for a month's supply, around 936 to 998 dollars depending on the year, and Wegovy's has been in the same neighborhood. The list price is the sticker on the system, the starting point for negotiations between the manufacturer, insurers, and pharmacy middlemen. Most people pay something very different: a copay if insurance covers it, a program price if they qualify for one, or a direct self-pay price from the manufacturer. The useful question is never what does it list for, it is what would I pay through each door I can actually walk through.
• Door one: insurance. Coverage follows the indication. Ozempic is approved for type 2 diabetes, and plans that cover it for diabetes often bring the monthly cost down to a manageable copay, with a manufacturer savings card on top for the commercially insured, sometimes as low as 25 dollars a month while the card's terms last. Wegovy, the weight-management semaglutide, is covered far less consistently, many employer plans and many state programs still exclude anti-obesity medication as a category, though that has been shifting year by year. Medicare historically could not cover weight-loss drugs, and the rules have been loosening in stages, so check the current year's position rather than an old article, including this one.
• Door two: manufacturer self-pay. Novo Nordisk sells directly to self-pay patients through its NovoCare pharmacy channel, launched in 2025, with Ozempic and Wegovy offered at flat monthly self-pay prices that began around 499 dollars, roughly half of list. Lilly does the same for its tirzepatide products through LillyDirect, including lower-priced Zepbound vials. In late 2025 the manufacturers also reached federal pricing agreements that are expected to push direct-purchase prices further down during 2026 for some channels and bring negotiated prices into Medicare. The honest summary: the self-pay direct price is the number to check first if insurance says no, and it has been moving in the patient's favor.
• The door we would skip: compounded semaglutide. During the shortage years, compounded semaglutide from pharmacies and telehealth sellers was often the cheapest door, sometimes 100 to 300 dollars a month. The FDA's position is worth knowing: compounded versions are not FDA-approved, the agency has warned about dosing errors and unverified ingredients, and once the shortage was declared resolved, the legal basis for mass-compounding copies largely ended. With manufacturer self-pay prices now far below the old list prices, the gap that made compounding tempting has narrowed. We do not link to or take money from any seller in this space, and our honest read is that the approved product through a legitimate channel is the option your prescriber can actually stand behind.

Frequently asked questions